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Core Curriculum in Nephrology

Diuretics in States of Volume Overload:
Core Curriculum 2022
James E. Novak and David H. Ellison
Volume overload, deﬁned as excess total body sodium and water with expansion of extracellular ﬂuid
volume, characterizes common disorders such as congestive heart failure, end-stage liver disease,
chronic kidney disease, and nephrotic syndrome. Diuretics are the cornerstone of therapy for volume
overload and comprise several classes whose mechanisms of action, pharmacokinetics, indications,
and adverse effects are essential principles of nephrology. Loop diuretics are typically the ﬁrst-line
treatment in the management of hypervolemia, with additional drug classes indicated in cases of
diuretic resistance and electrolyte or acid-base disorders. Separately, clinical trials highlight improved
outcomes in some states of volume overload, such as loop diuretics and sodium/glucose cotransporter 2 inhibitors in patients with congestive heart failure. Resistance to diuretics is a frequent,
multifactorial clinical challenge that requires creative and physiology-based solutions. In this installment
of AJKD’s Core Curriculum in Nephrology, we discuss the pharmacology and therapeutic use of diuretics in states of volume overload and strategies to overcome diuretic resistance.

Introduction
Case 1: A 56-year-old man is admitted to the
hospital with worsening dyspnea and 8-kg
weight gain and is diagnosed with acute
decompensated heart failure (ADHF). He has a
history of hypertension, type 2 diabetes, coronary artery disease, chronic kidney disease
(CKD) glomerular ﬁltration rate (GFR) category 3b and albuminuria category 2 (G3bA2),
and ischemic cardiomyopathy with ejection
fraction 30%. He is adherent to prescribed
medications, including losartan, furosemide
(40 mg twice daily), atorvastatin, and insulin.
Blood pressure (BP) is 162/92 mm Hg and
heart rate 104 beats per minute. Physical examination reveals an S3 gallop, bilateral
crackles, and pitting edema (3+). Admission
laboratory data include serum sodium level of
132 mEq/L, serum potassium level of 5.2 mEq/
L, serum urea nitrogen level of 63 mg/dL, and
serum creatinine (Scr) level of 2.1 mg/dL
(baseline, 1.4 mg/dL).
Question 1: Which of the following is the
next best step in management?
a) Prescribe furosemide intravenous
infusion
b) Prescribe metolazone
c) Prescribe dapagliﬂozin
d) Prescribe isolated ultraﬁltration
e) Discontinue losartan

(IV)

For the answer to the question, see the
following text.

Volume overload is defined as excess total
body sodium and water with expansion of
extracellular fluid volume. Volume overload

characterizes several common disorders, including congestive heart failure (CHF),
cirrhosis or end-stage liver disease (ESLD),
CKD (including kidney failure), and
nephrotic syndrome. The specific pathophysiology of these diseases varies, but most
patients present with one or more signs
or symptoms of hypertension, peripheral
edema, pulmonary congestion, and ascites.
The Agency for Healthcare Research and
Quality estimated that volume-overload
states such as CHF accounted for 1.1
million hospitalizations at a cost of $13.6
billion in the United States in 2017, whereas
kidney and liver disease hospitalizations cost
a combined $9.7 billion.
Diuretics are the cornerstone of therapy
for volume overload. There are several
classes of diuretics, whose mechanisms of
action, pharmacokinetics, and clinical use
constitute basic principles of nephrology.
Diuretic resistance is a frequent clinical
challenge caused by many factors (Box 1).
The patient in case 1 presents with ADHF
associated with resistance to oral furosemide. The best next step in management is
changing furosemide from oral to IV
dosing, thereby bypassing slowed absorption from gastrointestinal (GI) edema.
Additionally, most contemporary guidelines
suggest using 2-2.5 times the home dose
(here, 80-100 mg IV). Alternatively, furosemide could be changed to an equivalent
dose of bumetanide or torsemide; some
small studies have shown better intermediate outcomes with torsemide for symptomatic decongestion, but large outcomes

Complete author and article
information provided at end
of article.
Am J Kidney Dis. XX(XX):113. Published online month
xx, xxxx.
doi: 10.1053/
j.ajkd.2021.09.029

© 2021 by the National
Kidney Foundation, Inc.

FEATURE EDITOR
Asghar Rastegar
ADVISORY BOARD
Ursula C. Brewster
Michael Choi
Ann O’Hare
Biff F. Palmer
The Core Curriculum
aims to give trainees
in nephrology a
strong knowledge
base in core topics in
the specialty by
providing an overview of the topic and
citing key references,
including the foundational literature that
led to current clinical
approaches.

AJKD Vol XX | Iss XX | Month 2022
Downloaded for Anonymous User (n/a) at Henry Ford Hospital / Henry Ford Health System (CS North America) from ClinicalKey.com by
Elsevier on March 07, 2022. For personal use only. No other uses without permission. Copyright ©2022. Elsevier Inc. All rights reserved.

1

Novak and Ellison
Box 1. Causes of Diuretic Resistance, With Examples
• No volume overload (wrong diagnosis)
B Venous stasis
B Lymphedema, lipedema
• Nonadherence
B Excess salt intake
B Nonadherence to medication
• Decreased drug delivery
B Decreased absorption (gut edema)
B Inadequate dose/frequency
B Hypoalbuminemia
• Decreased drug secretion
B Decreased kidney blood ﬂow: AKI/CKD, decreased
EABV
B Tubule transport inhibition: FFAs, bile acids, organic
acids, NSAIDs, indoxyl sulfate, p-cresyl sulfate
B Decreased kidney mass
• Decreased kidney response
B Distal tubule hypertrophy
B Renin-angiotensin-aldosterone activation
Based on information in Hoorn and Ellison, 2017(Am J Kidney Dis. https://doi.
org/10.1053/j.ajkd.2016.08.027). Abbreviations: AKI, acute kidney injury; CKD,
chronic kidney disease; EABV, effective arterial blood volume; FFA, free fatty
acid; NSAID, nonsteroidal anti-inﬂammatory drug.

studies conflict as to whether loop diuretic choice affects long-term outcomes, including mortality. Metolazone could be added to block distal tubule sodium
reabsorption in conjunction with, but not in place of,
IV furosemide. Dapagliflozin improves outcomes in
CHF but would not replace an IV loop diuretic for
prompt decongestion. Isolated ultrafiltration removes
fluid as effectively as furosemide but is associated with
more frequent adverse events. Stopping losartan may
be necessary if acute kidney injury (AKI) or hyperkalemia worsen, but these conditions frequently
improve with diuresis alone. So, the correct answer to
question 1 is (a).
In this installment of AJKD’s Core Curriculum in
Nephrology, we discuss the pharmacology and therapeutic use of diuretics in states of volume overload.
We also review strategies to overcome diuretic
resistance.

a)
b)
c)
d)
e)

Furosemide 120 mg twice daily and metolazone 10 mg/d
Furosemide 80 mg twice daily
Furosemide 160 mg/d
Bumetanide 4 mg twice daily
Bumetanide 4 mg/d

For the answer to the question, see the following text.

Pharmacokinetics describe how a drug is absorbed,
distributed, metabolized, and eliminated by the body.
For example, furosemide is absorbed similarly in the
stomach and duodenum, although gastric absorption is
slow and includes first-pass metabolism. This effect may
account for the lower (50%-60%) bioavailability of
furosemide compared with other loop diuretics such as
bumetanide and torsemide (>80%). Such differences in
bioavailability have implications for IV-to-oral dosing
conversions: generally, the furosemide dose should be
doubled when making this change, whereas bumetanide
and torsemide doses should stay the same, although these
rules are only approximations. Ultimately, the effective
dose is determined by the urine output response. GI tract
edema decreases the velocity but not the total amount of
furosemide absorbed. However, this slowed absorption
may prevent orally administered furosemide from
reaching its threshold plasma concentration (Fig 1A).
Finally, the dose-response curve for loop diuretic agents
is sigmoidal and logarithmic, so exponential dose increases may be needed for patients who do not show a
response to an algorithmic or empirical dose (Fig 1B).
Conversely, doses that yield plasma concentrations
greater than the ceiling may increase toxicity without
increasing response.
Once absorbed, most diuretics bind to serum albumin
for distribution, followed by metabolism and elimination
by the liver and kidneys. Hypoalbuminemia and impaired
renal blood flow (as in AKI and CKD) decrease diuretic
delivery, so albumin and loop diuretic coinfusion has
been proposed to improve drug response, but this

Pharmacokinetics
Case 1, continued: Furosemide 40 mg IV followed by an
infusion of 5 mg/h is administered, and urine output increases to 2.4 L/d. After 2 days, the patient’s dyspnea and
peripheral edema have improved, and BP has decreased to
146/84 mm Hg. Scr has also decreased from 2.1 to 1.7 mg/
dL. Preparing the patient for discharge, the inpatient team
converts medications from IV to oral dosing and schedules
primary care follow-up within 1 week.
Question 2: Which of the following is the most
appropriate diuretic regimen for discharge?

2

Figure 1. (A) Plasma diuretic concentration versus time. Dashed
lines show natriuretic thresholds for individuals with and without
edema. (B) Dose-response curve for loop diuretic plasma concentration. Abbreviations: IV, intravenous; PO, oral. Reproduced
from Ellison, 2019 (Clin J Am Soc Nephrol. https://doi.org/1
0.2215/cjn.09630818) with permission of the copyright holder.
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practice has not been beneficial in critically ill adult patients. Furosemide is metabolized completely by the
kidneys (35% furosemide glucuronide and 65% parent
molecule excretion), whereas torsemide is metabolized
mainly by the liver. Triamterene is a prodrug that
requires hepatic activation to hydroxytriamterene, so it
is relatively ineffective in ESLD. Routes of diuretic
metabolism and elimination may be important considerations for patients with kidney or liver disease
(Table 1).
Peak serum concentrations of loop diuretics occur
within 0.5-2 hours, even though drug effects may last
for 6-8 hours, especially with impaired kidney, heart,
or liver function. The short elimination half-life (t1/2)
of most loop diuretics, except possibly torsemide,
means they are typically dosed at least twice daily.
Despite this short t1/2, more frequent administration
than twice daily is usually unnecessary because sodium
intake is zero during sleep. Conversely, if loop diuretics are prescribed only once daily, the kidneys are
diuretic-free for many hours, allowing considerable
rebound sodium reabsorption in most cases. On the
contrary, thiazide and distal diuretics have much
longer t1/2 values and may be given daily. A new
extended-release preparation of torsemide has been
approved by the US Food and Drug Administration
(FDA) for the treatment of edema from heart and
kidney failure.
In case 1, the patient was initially prescribed a furosemide loading dose of 80 mg IV to rapidly achieve a
therapeutic serum level, followed by a maintenance
dose of 5 mg/h (120 mg/d) IV to maintain a steady
state; this management strategy has effectively achieved

decongestion. This dose is equivalent to 240 mg/
d orally, which should be given as 120 mg twice daily to
avoid postdiuretic sodium reabsorption. However,
because this patient’s signs and symptoms of ADHF and
AKI resolved and 2.4 L/d urine output is no longer
necessary, a lower oral dose of furosemide, such as 80
mg twice daily, may be appropriate. Furosemide 120 mg
twice daily with metolazone 10 mg/d would further
increase diuresis and could cause hypovolemia and/or
hypokalemia. Similarly, bumetanide 4 mg orally twice
daily, which is equivalent to furosemide 160 mg IV twice
daily or 320 mg orally twice daily, would also risk
hypovolemia. Unless sodium intake can be severely
restricted, neither furosemide nor bumetanide should be
dosed once daily. The correct answer to question 2 is (b).
Additional Readings
➢ Brater DC. Update in diuretic therapy: clinical pharmacology. Semin Nephrol. 2011;31(6):483-494.
+ESSENTIAL READING

➢ Doungngern T, Huckleberry Y, Bloom JW, Erstad B.
Effect of albumin on diuretic response to furosemide in
patients with hypoalbuminemia. Am J Crit Care.
2012;21(4):280-286.
➢ Gottlieb SS, Khatta M, Wentworth D, Roffman D, Fisher
ML, Kramer WG. The effects of diuresis on the pharmacokinetics of the loop diuretics furosemide and
torsemide in patients with heart failure. Am J Med.
1998;104(6):533-538.
➢ Hoorn EJ, Ellison DH. Diuretic Resistance. Am J Kidney
Dis. 2017;69(1):136-142. +ESSENTIAL READING
➢ Huang X, Dorhout Mees E, Vos P, Hamza S, Braam B.
Everything we always wanted to know about

Table 1. Pharmacokinetics of Diuretics
Diuretic
Loop
Furosemide
Bumetanide
Torsemide
Thiazide
HCTZ
Chlorthalidone
Metolazone
Distal
Amiloride
Triamterene
Spironolactone

Elimination t1/2, h

Bioavailability

Equivalent
Dose, mg

Metabolism
(Kidney/Liver)

Normal

CKD

CHF

ESLD

50%-60% (10%-100%)a
80%-100%
68%-100%

40
1
20

100%/0%
50%/50%
20%/80%

1.5-2
1
3-4

2.6-2.8
1.6
4-5

2.7
1.3
6

2.5
2.3
8

65%-75%
60%-72%
65%-90%

25
12.5
2.5

100%/0%
100%/0%
70%-95%/5%-30%

6-15
40-60
14-20

↑
↑
↑

↔
↔
↔

↔
↔
↔

50%
52%-80%
>90%

10
100
25

50%/–b
20%/80%
0%/100%

6-26
2-5
>15d

100
↑
↔

?
?
?

↔
–c
↔

Based on information in Hoorn and Ellison, 2017 (Am J Kidney Dis. https://doi.org/10.1053/j.ajkd.2016.08.027). Abbreviations: t1/2, half-life; AKI, acute kidney injury; CHF,
congestive heart failure; CKD, chronic kidney disease; EABV, effective arterial blood volume; ESLD, end-stage liver disease; FFA, free fatty acid; HCTZ,
hydrochlorothiazide.
a
The usual range is taken as 50%-60%, but some have reported a range as great as 10%-100%.
b
Amiloride is 50% excreted in the stool.
c
Triamterene requires hepatic activation and is considered inactive in ESLD.
d
Spironolactone undergoes rapid hepatic breakdown to active metabolites; parent molecule elimination t1/2 = 1.5 h.
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➢

➢

➢

➢
➢

furosemide but were afraid to ask. Am J Physiol Renal
Physiol. 2016;310(10):F958-971. +ESSENTIAL READING
Lee WI, Yoon WH, Shin WG, Song IS, Lee MG. Pharmacokinetics and pharmacodynamics of furosemide
after direct administration into the stomach or duodenum. Biopharm Drug Dispos. 1997;18(9):753-767.
Mahmoodpoor A, Zahedi S, Pourakbar A, et al. Efficacy
of furosemide-albumin compared with furosemide in
critically ill hypoalbuminemia patients admitted to
intensive care unit: a prospective randomized clinical
trial. Daru. 2020;28(1):263-269.
Shah S, Pitt B, Brater DC, et al. Sodium and fluid
excretion with torsemide in healthy subjects is limited
by the short duration of diuretic action. J Am Heart Assoc.
2017;6(10):e006135.
Shankar SS, Brater DC. Loop diuretics: from the Na-K2Cl transporter to clinical use. Am J Physiol Renal Physiol.
2003;284(1):F11-F21.
Vasko MR, Cartwright DB, Knochel JP, Nixon JV, Brater
DC. Furosemide absorption altered in decompensated
congestive
heart
failure.
Ann
Intern
Med.
1985;102(3):314-318.

Classes of Diuretics
Case 2: A 63-year-old woman presents to the clinic for
ongoing management of CHF from ischemic cardiomyopathy (ejection fraction 22%) and CKD G3bA2 from type 2
diabetes. She has been hospitalized repeatedly with hyperkalemia, AKI, and ADHF, and lisinopril was ﬁnally discontinued after several attempts to maintain a dose of 2.5-5
mg/d. She is currently taking furosemide 40 mg twice daily
and now reports slightly increased edema but no difﬁculty
breathing. BP is 146/86 mm Hg, heart rate 68 beats per
minute, and respiratory rate 14 per minute. Physical examination reveals an S3 gallop, clear lung ﬁelds, and pitting
edema (2+). Serum potassium level is 5.6 mEq/L, total CO2
level is 40 mEq/L, and Scr is 1.5 mg/dL (at baseline). Arterial
blood gas reveals pH 7.49, partial pressure of CO2 of 55 mm
Hg, partial pressure of O2 of 90 mm Hg, and bicarbonate
level of 41 mEq/L.
Question 3: Which of the following is the next best
step in management?
a) Increase furosemide to 80 mg twice daily
b) Prescribe chlorthalidone 12.5 mg/d

Figure 2. Sites of sodium reabsorption and diuretic action. Abbreviations: Aml, amiloride (and triamterene); CAI, carbonic anhydrase
inhibitors; DCTD, distal convoluted tubule diuretics (eg, thiazides); LD, loop diuretics; MR, mineralocorticoid receptor. Reproduced
from Ellison, 2019 (Clin J Am Soc Nephrol. https://doi.org/10.2215/cjn.09630818) with permission of the copyright holder.
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c) Prescribe spironolactone 25 mg/d
d) Prescribe acetazolamide 250 mg/d
e) Prescribe sodium zirconium cyclosilicate 10 g/d
For the answer to the question, see the following text.

Sulfonamides

Sulfonamides are characterized by a –SO2NH2 group and
include loop diuretics, benzothiadiazide or thiazide-like
diuretics (thiazides), and carbonic anhydrase (CA) inhibitors (CAIs). Because these drugs are 91%-99%
albumin-bound anions, they are first taken up by
proximal tubule cells by organic anion transporters
(OATs) and are then secreted into the urine via
multidrug resistance-associated protein 4 (MRP4).
Although sulfonamide diuretics are categorized by
their primary site of action (Fig 2), several drugs act
at more than one site, causing overlap between
the classes. For instance, the thiazide diuretics hydrochlorothiazide (HCTZ) and metolazone block not
only the distal sodium/chloride cotransporter (NCC)
but also the proximal tubule sodium/hydrogen
exchanger or CA, respectively, and thus act as weak
CAIs as well.
Sulfonamide diuretics are often avoided in sulfa-allergic
patients, but this practice may be unwarranted because
most patients who report a sulfa allergy can tolerate them.
Allergic reactions to these drugs seem to result from
generalized hypersensitivity rather than specific crossreactivity to the sulfonamide group. Sulfonamide antibiotics contain an aromatic amine and undergo hepatic
oxidation to hydroxylamines, which may mediate allergic
reactions in susceptible patients, whereas sulfonamide diuretics do not contain this aromatic amine and are
metabolized differently.
Additional Readings
➢ Baranauskiene L, Skiudaite L, Michailoviene V, et al.
Thiazide and other Cl-benzenesulfonamide-bearing
clinical drug affinities for human carbonic anhydrases.
PLoS One. 2021;16(6):e0253608.
➢ Beaumont K, Vaughn DA, Fanestil DD. Thiazide
diuretic drug receptors in rat kidney: identification
with [3H]metolazone. Proc Natl Acad Sci U S A.
1988;85(7):2311-2314.
➢ Hasannejad H, Takeda M, Taki K, et al. Interactions of
human organic anion transporters with diuretics. J
Pharmacol Exp Ther. 2004;308(3):1021-1029.
➢ Sinke AP, Kortenoeven ML, de Groot T, et al. Hydrochlorothiazide attenuates lithium-induced nephrogenic
diabetes insipidus independently of the sodiumchloride cotransporter. Am J Physiol Renal Physiol.
2014;306(5):F525-F533.
➢ Strom BL, Schinnar R, Apter AJ, et al. Absence of crossreactivity between sulfonamide antibiotics and

sulfonamide nonantibiotics. N Engl J Med.
2003;349(17):1628-1635. +ESSENTIAL READING
➢ Wulf NR, Matuszewski KA. Sulfonamide crossreactivity: is there evidence to support broad crossallergenicity?
Am
J
Health
Syst
Pharm.
2013;70(17):1483-1494.
Loop Diuretics

Loop diuretics antagonize the sodium/potassium/
chloride cotransporter (NKCC2) in the thick ascending
limb of the loop of Henle. This drug class includes the
sulfonamides furosemide, bumetanide, and torsemide
and the nonsulfonamide ethacrynic acid. Loop diuretics
also block sodium chloride reabsorption through an
NKCC2 splice variant in the macula densa, disrupting
tubuloglomerular feedback and maintaining GFR
despite ongoing diuresis. Blockade of sodium chloride
entry into macula densa cells also causes volumeindependent renin release from the juxtaglomerular
apparatus
and
subsequent
renin-angiotensinaldosterone system (RAS) activation. Because the
thick ascending limb reabsorbs 20%-25% of the
filtered sodium load, these drugs are among the
strongest diuretics available.
Loop diuretics cause several adverse effects. Hypotension
is caused by diuresis as well as, and more immediately, by
vasodilation from vascular sodium/potassium/chloride
cotransporter (NKCC1) inhibition. Hypokalemia and
metabolic alkalosis result from increased sodium delivery to
the distal nephron and activation of the RAS (Table 2). By
blocking potassium recycling (into the cell via NKCC2 and
back to the lumen via the renal outer medullary K [ROMK]
channel), loop diuretics reduce the lumen-positive voltage
gradient in the thick ascending limb, thereby inhibiting
paracellular calcium and magnesium reabsorption (Fig 3).
Loop diuretics may cause hyperuricemia, probably by
competitively inhibiting urate excretion via OAT, MRP4, or
sodium phosphate transporter 4 in the proximal tubule.
Importantly, NKCC2 antagonism deprives the renal medulla
of half of the osmolytes it needs to maintain hypertonicity,
preventing water reabsorption and occasionally causing
hypernatremia. Ototoxicity is an uncommon complication
of loop diuretics and includes reversible ischemia and
disruption of cochlear action potentials, as well as irreversible hair cell loss, notably when high doses (eg,
furosemide ≥25 mg/min IV) are given with
aminoglycosides.
Additional Readings
➢ Ben Salem C, Slim R, Fathallah N, Hmouda H. Druginduced hyperuricaemia and gout. Rheumatology.
2016;56(5):679-688.
➢ Delpire E. Advances in the development of novel
compounds targeting cation-chloride cotransporter
physiology. Am J Physiol Cell Physiol. 2021;320(3):C324C340.
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Table 2. Effects of Diuretics on Serum Concentration of Electrolytes, Acid-Base Balance, and Other Parameters
Serum Concentration
Class
Loop
Thiazide
CAI
K-sparing
SGLT2i
Vaptan
Osmotic

K+
↓
↓
↓
↑
↔/↑
↔/↓
↑↓c

Ca2+
↓
↑
↓
↑a
↔
↔
↓

Mg2+
↓
↓
↓
↑
↑
↔
↓

Urate↑
↑
↔
↑
↓
↔
↓

Na+
↑
↓
↓
↑↓b
↑
↑
↑↓c

H+
↓
↓
↑
↑
↔
↔
↑

Miscellaneous
Ototoxicity with AG
Insulin resistance
CaP stones
Androgen blockade
Euglycemic DKA
–
–

Based on information in Greenberg, 2000 (Am J Med Sci. 319[1]:10-24). Abbreviations: AG, aminoglycoside; CAI, carbonic anhydrase inhibitor; DKA, diabetic ketoacidosis; SGLT2i, sodium/glucose cotransporter 2 inhibitor.
a
Spironolactone has little effect on calcium reabsorption.
b
Amiloride and triamterene are associated with water excretion, whereas spironolactone and eplerenone are associated with water retention.
c
Translocational hyponatremia and hyperkalemia may occur during drug infusion, whereas hypernatremia and hypokalemia may occur during diuresis.

➢ Ding D, Liu H, Qi W, et al. Ototoxic effects and
mechanisms of loop diuretics. J Otol. 2016;11(4):145156.
➢ Gamba G. Molecular physiology and pathophysiology
of electroneutral cation-chloride cotransporters. Physiol
Rev. 2005;85(2):423-493.
Thiazide Diuretics

Thiazides block NCC in the distal convoluted tubule
(DCT). This class of diuretics includes the benzothiadiazine
derivatives HCTZ and chlorothiazide as well as the
thiazide-like diuretics chlorthalidone, metolazone, and
indapamide. As the DCT normally reabsorbs only 5%-10%

Figure 3. Paracellular calcium and magnesium absorption in the
thick ascending limb of the loop of Henle. Loop diuretics block
the sodium/potassium/chloride cotransporter. Abbreviations:
CLC-NKB, chloride channel; NKCC2, sodium/potassium/chloride cotransporter; ROMK, renal outer medullary potassium
channel. Based on information in Mount, 2014 (Clin J Am Soc
Nephrol.
https://doi.org/10.2215/cjn.04480413).
Image
created with BioRender.
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of the filtered sodium load, thiazides by themselves are
relatively weak diuretics.
Thiazides significantly decrease BP, an effect caused by
natriuresis and vasodilation. Similarly to loop diuretics,
thiazides produce hypokalemia, hyperuricemia, and
metabolic alkalosis, but hypokalemia is more common
with thiazides. Thiazides inhibit a “potassium switch” in
the distal nephron, which plays an essential role in potassium reabsorption by the kidneys. Thiazides also increase calcium reabsorption (1) in the proximal tubule
from volume contraction and (2) in the DCT from
increased basolateral sodium/calcium exchange and
luminal calcium influx (Fig 4). Conversely, thiazides
decrease magnesium reabsorption in the DCT, possibly by
blocking the luminal magnesium channel and the basolateral adenosine triphosphatase sodium/potassium pump

Figure 4. Transcellular calcium and magnesium absorption in
the distal convoluted tubule. Abbreviations: Kv1.1, voltagegated K channel; NCX1, sodium/calcium exchanger; TRPM6,
transient receptor potential melastatin 6 Mg channel; TRPV5,
transient receptor potential vanilloid 5 Ca channel. Based on information in Blaine et al, 2015 (Clin J Am Soc Nephrol. https://
doi.org/10.2215/cjn.09750913). Image created with BioRender.
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(Na+/K+-ATPase). Hyponatremia from these drugs has
been attributed to sodium depletion, antidiuretic hormone
release, and preexisting prostaglandin receptor polymorphisms. Finally, hyperglycemia from thiazides may be
caused by hypokalemia-mediated inhibition of insulin
release.
Additional Readings
➢ Ellison DH, Terker AS, Gamba G. Potassium and its
discontents: new insight, new treatments. J Am Soc
Nephrol. 2016;27(4):981-989.
➢ Filippone EJ, Ruzieh M, Foy A. Thiazide-associated
hyponatremia: clinical manifestations and pathophysiology. Am J Kidney Dis. 2020;75(2):256-264.
➢ Maeoka Y, McCormick JA. NaCl cotransporter activity
and Mg(2+) handling by the distal convoluted tubule.
Am J Physiol Renal Physiol. 2020;319(6):F1043-F1053.
➢ Palmer BF. Metabolic complications associated with use
of diuretics. Semin Nephrol. 2011;31(6):542-552.
+ESSENTIAL READING

➢ Rapoport RM, Soleimani M. Mechanism of thiazide
diuretic arterial pressure reduction: the search continues. Front Pharmacol. 2019;10:815.
CAIs
CAs are widely expressed across kingdoms of living organisms and within many tissues, so CAIs are useful in
treating disorders other than volume overload (eg, seizures, glaucoma, altitude sickness, obesity, and cancer). In
the kidneys, 95% of CA is intracellular CA-II and 5% is

Figure 5. Carbonic anhydrase (CA) in the proximal tubule. Inhibition of CA-IV blocks production of intracellular hydrogen ions,
which inhibits NHE3 and causes excretion of sodium ions. Inhibition of CA-II blocks consumption of luminal bicarbonate
(HCO3−), which is excreted as sodium bicarbonate (NaHCO3).
Abbreviations: NHE3, sodium/hydrogen exchanger; NBCE1-a,
sodium/bicarbonate cotransporter. Based on information in
Hamm et al, 2015 (Clin J Am Soc Nephrol. https://doi.org/1
0.2215/cjn.07400715). Image created with BioRender.

membrane-bound CA-IV, and both isoforms are expressed
in proximal tubule cells and α-intercalated cells, among
others. The best-known CAI is the sulfonamide acetazolamide, but CAIs may derive from other drug classes (eg,
phenols, polyamines, thiazides, and coumarins) and
include medications such as anticonvulsant agents (eg,
topiramate, lacosamide, zonisamide). Proximal sodium
wasting is attenuated by distal sodium reabsorption, so
CAIs have limited diuretic potency (Fig 5).
As with the other sulfonamides, CAIs may cause hypovolemia and hypokalemia by increasing sodium excretion. Of
the total filtered load, 60%-70% of calcium and 10%-25% of
magnesium is reabsorbed by the proximal tubule, so CAIs
may also precipitate hypocalcemia or hypomagnesemia.
However, the unique property of CAIs is bicarbonate excretion, resulting in urinary alkalinization and metabolic
acidosis. Hypercalciuria and alkalinuria, as well as hypocitraturia caused by intracellular acidosis, favor the formation of
calcium phosphate stones in 10% of patients receiving CAIs.
Additional Readings
➢ Alexander RT, Dimke H. Effect of diuretics on renal
tubular transport of calcium and magnesium. Am J
Physiol Renal Physiol. 2017;312(6):F998-F1015.
➢ Daudon M, Frochot V, Bazin D, Jungers P. Druginduced kidney stones and crystalline nephropathy:
pathophysiology, prevention and treatment. Drugs.
2018;78(2):163-201.
➢ Hamm LL, Nakhoul N, Hering-Smith KS. Acid-base
homeostasis. Clin J Am Soc Nephrol. 2015;10(12):22322242.
➢ Purkerson JM, Schwartz GJ. The role of carbonic
anhydrases in renal physiology. Kidney Int.
2007;71(2):103-115.
➢ Supuran CT. Carbonic anhydrase inhibitors: an editorial. Expert Opin Ther Pat. 2013;23(6):677-679.
Potassium-Sparing Diuretics
The potassium-sparing diuretics include 2 drug classes,
epithelial sodium channel (ENaC) blockers and mineralocorticoid receptor antagonists (MRAs). The ENaC blockers,
amiloride and triamterene, block sodium entry into the
principal cell, generating a weak diuresis. Critically, ENaC
inhibition disrupts the normal lumen-negative potential in
the collecting duct, inhibiting potassium and hydrogen ion
secretion and promoting calcium and magnesium
reabsorption.
The MRAs include, in order of increasing mineralocorticoid receptor selectivity, spironolactone, eplerenone,
and finerenone. Finerenone is the first of a new class of
nonsteroidal MRAs. Unlike most other diuretics, these
steroid hormone inhibitors reach their site of action by
basolateral diffusion rather than luminal secretion. As with
ENaC blockers, MRAs act in the principal cell, blocking
aldosterone-stimulated ENaC, ROMK, and Na+/K+-ATPase
activity. Similarly, these drugs are weak diuretics and also
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cause potassium, magnesium, and hydrogen ion retention,
although calcium handling is unaffected. Antiandrogen
side effects are greatest with spironolactone and include
gynecomastia, dysmenorrhea, and impotence. MRAs are
useful in managing hypertension, CHF, and CKD, in part
by decreasing inflammation and fibrosis. Finerenone was
recently approved by the FDA to decrease the risk of CKD
progression and cardiovascular events in patients with
diabetic kidney disease.
The patient in case 2 requires ongoing diuresis but has
developed hyperkalemia and metabolic alkalosis.
Increasing the dose of furosemide or prescribing chlorthalidone would worsen metabolic alkalosis, whereas
prescribing spironolactone would worsen hyperkalemia.
Prescribing sodium zirconium cyclosilicate, a potassium
binder with a high sodium content, would decrease the
serum potassium level but could exacerbate volume
overload. Prescribing acetazolamide would increase sodium, potassium, and bicarbonate excretion, improving
hypervolemia, hyperkalemia, and metabolic alkalosis,
respectively. Thus, the answer to question 3 is (d).
Additional Readings
➢ Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2
diabetes. N Engl J Med. 2020;383(23):2219-2229.
➢ Georgianos PI, Agarwal R. Resistant hypertension in
chronic kidney disease (CKD): prevalence, treatment
particularities, and research agenda. Curr Hypertens Rep.
2020;22(10):84.
➢ Patel V, Joharapurkar A, Jain M. Role of mineralocorticoid receptor antagonists in kidney diseases. Drug Dev
Res. 2021;82(3):341-363. +ESSENTIAL READING
➢ Rico-Mesa JS, White A, Ahmadian-Tehrani A, Anderson
AS. Mineralocorticoid receptor antagonists: a comprehensive review of finerenone. Curr Cardiol Rep.
2020;22(11):140.
Sodium/Glucose Cotransporter 2 Inhibitors
Sodium/glucose cotransporter 2 (SGLT2) inhibitors
reduce sodium and glucose reabsorption from the proximal tubule. Originally developed as hypoglycemic agents,
SGLT2 inhibitors have pleiotropic physiological benefits,
including decreased inflammation and mild diuresis. Like
other drug classes that cause functional decreases in GFR,
such as angiotensin-converting enzyme inhibitors, SGLT2
inhibitors acutely reduce GFR by restoring tubuloglomerular feedback but preserve kidney function with longterm use, possibly by attenuating glomerular hypertension.
SGLT2 inhibitors improve clinical outcomes, such as
slowing the progression of diabetic and nondiabetic CKD
and decreasing the risk of AKI, CHF hospitalization, and
cardiovascular mortality. Improved heart failure outcomes
seem unlikely to be attributable solely to diuresis, but
SGLT2 inhibitors may help with decongestion; alternatively, SGLT2 inhibitors may confer benefit by mimicking
8

fasting physiology through adaptive cellular reprogramming. Although guidelines are still evolving regarding the
use of these drugs, decreasing the dose of other diuretics
may be reasonable when prescribing SGLT2 inhibitors to
patients with euvolemia. Other effects of SGTL2 inhibitors
include uricosuria, genital and urinary tract infection, and
euglycemic diabetic ketoacidosis.
Additional Readings
➢ Anders HJ, Davis JM, Thurau K. Nephron protection in
diabetic
kidney
disease.
N
Engl
J
Med.
2016;375(21):2096-2098.
➢ Heerspink HJL, Stefansson BV, Correa-Rotter R, et al.
Dapagliflozin in patients with chronic kidney disease. N
Engl J Med. 2020;383(15):1436-1446.
➢ Hou YC, Zheng CM, Yen TH, Lu KC. Molecular
mechanisms of SGLT2 inhibitor on cardiorenal protection. Int J Mol Sci. 2020;21(21):7833.
➢ McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced
ejection fraction. N Engl J Med. 2019;381(21):19952008.
➢ Packer M. SGLT2 Inhibitors produce cardiorenal benefits by promoting adaptive cellular reprogramming to
induce a state of fasting mimicry: a paradigm shift in
understanding their mechanism of action. Diabetes Care.
2020;43(3):508-511.
➢ Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and
renal outcomes in type 2 diabetes and nephropathy. N
Engl J Med. 2019;380(24):2295-2306. +ESSENTIAL READING
Vasopressin Receptor Antagonists
Although diuretics agents are traditionally natriuretic
drugs, vasopressin receptor antagonists (VRAs) are aquaretic agents, which increase free water excretion. These
agents, such as tolvaptan and conivaptan, are inverse agonists at the vasopressin V2 receptor in the collecting duct.
VRAs were designed to manage hyponatremia associated
with the syndrome of inappropriate antidiuretic hormone,
ESLD, and CHF. In patients with CHF, tolvaptan acutely
increases serum sodium and decreases body weight but
does not improve long-term CHF morbidity or mortality.
Tolvaptan caused a nonsignificant increased risk of GI
bleeding in one trial of patients with ESLD, and conivaptan
also blocks splanchnic V1 receptors, theoretically aggravating variceal dilation and bleeding. Finally, in the
TEMPO (Tolvaptan Efficacy and Safety in Management of
Autosomal Dominant Polycystic Kidney Disease and its
Outcomes) 3:4 trial, 1,445 patients with early-stage CKD
randomized to receive tolvaptan versus placebo showed an
increased risk of liver aminotransferase level increase
(0.9% vs 0.4%, respectively). For these reasons, the FDA
limits VRA therapy for hyponatremia to 30 days and recommends against their use in ESLD. VRA-mediated free
water excretion causes polyuria, thirst, and ultimately
hypernatremia, as well as hypokalemia from increased
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urine flow. The role of VRAs in patients with volume
overload requires further study.
Additional Readings
➢ Alukal JJ, John S, Thuluvath PJ. Hyponatremia in
cirrhosis:
an
update.
Am
J
Gastroenterol.
2020;115(11):1775-1785.
➢ Cardenas A, Gines P, Marotta P, et al. Tolvaptan, an oral
vasopressin antagonist, in the treatment of hyponatremia in cirrhosis. J Hepatol. 2012;56(3):571-578.
➢ Konstam MA, Gheorghiade M, Burnett JC Jr, et al. Effects of oral tolvaptan in patients hospitalized for
worsening heart failure: the EVEREST Outcome Trial.
JAMA. 2007;297(12):1319-1331.
➢ Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a
selective oral vasopressin V2-receptor antagonist, for
hyponatremia. N Engl J Med. 2006;355(20):2099-2112.

volume expansion upon entry into the bloodstream, with
electrolyte changes (hyponatremia, hyperkalemia) that
may reverse when diuresis has occurred (hypernatremia,
hypokalemia). This initial volume expansion may be severe enough to cause pulmonary edema in the case of
rapid mannitol infusion. Because of these time-varying
effects on volume status, osmotic diuretics are not used
to manage volume overload, but are useful for decreasing
intracranial pressure in cerebral edema (mannitol) and
increasing free water excretion in hyponatremia (urea).
Additional Readings
➢ Lang F. Osmotic diuresis. Ren Physiol. 1987;10(34):160-173.
➢ Mathisen O, Raeder M, Kiil F. Mechanism of osmotic
diuresis. Kidney Int. 1981;19(3):431-437.

+ESSENTIAL READING

➢ Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in
patients with autosomal dominant polycystic kidney
disease. N Engl J Med. 2012;367(25):2407-2418.
+ESSENTIAL READING

➢ Wu MY, Chen TT, Chen YC, et al. Effects and safety of
oral tolvaptan in patients with congestive heart failure:
a systematic review and network meta-analysis. PLoS
One. 2017;12(9):e0184380.
Osmotic Diuretics
Osmotic diuretics are distinct from the others in that they
do not act at specific transporters or receptors. These
agents, such as mannitol and urea, are freely filtered at the
glomerulus and remain in the tubular lumen, reversing the
usual 3-5 mOsm/kg H2O lumen-to-interstitium osmotic
pressure difference. Iso-osmotic water and electrolyte
reabsorption is inhibited in water-permeable nephron
segments, such as the proximal tubule and thin descending
limb of the loop of Henle, disrupting countercurrent exchange and the medullary concentration gradient. Moreover, membrane-impermeable agents (ie, effective
osmoles) cause cellular dehydration and intravascular

Table 3. Stepwise Diuretic Dosing Algorithm From CARRESSHF
Furosemide Dose
Level
A
B
C
D

Current
≤80 mg/d
81-160 mg/d
161-240 mg/d
≥240 mg/d

Suggested
(Bolus, Infusion)
40 mg, 5 mg/h
80 mg, 10 mg/h
80 mg, 20 mg/h
80 mg, 30 mg/h

Suggested
Metolazone
Dose
0
5 mg/d
5 mg 2×/d
5 mg 2×/d

Therapy was escalated to the next level if 3 L/d urine output was not achieved;
other medical and technical interventions were also allowed. Based on information
in Bart et al, 2012 (J Card Fail. https://doi.org/10.1016/j.cardfail.2011.12.009).
Abbreviation: CARRESS-HF, Cardiorenal Rescue Study in Acute Decompensated
Heart Failure.

Managing Volume Overload and Diuretic
Resistance
Heart Failure
As reviewed in cases 1 and 2, loop diuretic agents are the
workhorses for decongestion in CHF. Upon hospital
admission for ADHF, loop diuretics are usually given IV
and at higher doses, such as per the algorithm from the
Cardiorenal Rescue Study in Acute Decompensated Heart
Failure (CARRESS-HF; Table 3). This trial included patients with ADHF and AKI and targeted 3-5 L/d urine
output. The Diuretic Optimization Strategies Evaluation
(DOSE) trial confirmed that patients receiving more
furosemide (2.5 times the home dose) compared with
those receiving the home dose given IV experienced
more weight loss and dyspnea relief, and that twice-daily
administration performed as well as continuous infusion.
Despite the latter finding, some clinicians prefer continuous infusion to twice-daily administration, especially
when frequent dose changes may be desired because of
clinical instability. Although torsemide or bumetanide
have been touted as superior to furosemide because of
better bioavailability, and, in the case of torsemide,
longer t1/2, clinical trials demonstrating improved
readmission rates and symptom scores did not routinely
allocate patients to bioequivalent diuretic doses,
and mortality benefits have been contested. Interestingly,
spontaneous Scr increases from ADHF are associated
with increased mortality and more frequent hospital
readmission, whereas iatrogenic increases in Scr from
successful diuresis are associated with decreased mortality, as long as decongestion is occurring.
Resistance to diuresis may follow from any of the
causes in Box 1. The braking phenomenon occurs when
the kidneys’ initially robust natriuretic response wanes
as extracellular fluid volume decreases. This phenomenon
has been attributed to RAS activation by CHF and extracellular fluid volume depletion, stimulating sodium
reabsorption throughout the nephron, in conjunction
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with distal tubule hypertrophy or remodeling, whereby
long-term NKCC2 blockade in the loop of Henle
causes NCC upregulation in the DCT. Consequently,
thiazides may be added to maximal doses of loop
diuretics (ie, furosemide 160-320 mg/d IV) to augment
urine output. All thiazides seem equally efficacious,
and their long t1/2 makes timing of their administration
with loop diuretic agents unnecessary (ie, 30 minutes
before).
As previously mentioned, and separate from decongestion, add-on therapy with dapagliflozin and spironolactone or eplerenone improves morbidity and
mortality in patients with systolic CHF. Similarly, VRAs
and CAIs are reasonable additions in patients with refractory hyponatremia or metabolic alkalosis, respectively, but their long-term benefits are unproven.
Tolvaptan, specifically, has been studied in numerous
randomized controlled trials in patients with CHF, and,
even though findings are inconclusive, post hoc analysis
of 2 of the largest trials has shown improved outcomes
in patients with serum sodium levels <130 mEq/L.
Vaptans are currently under investigation as adjunctive
agents to first-line diuretic agents. Although more data
are needed, isolated ultrafiltration has been linked to
more frequent adverse events without more weight loss
compared with IV furosemide. Compared with furosemide alone, hypertonic saline solution plus furosemide
has been reported to improve diuresis, hospital readmission, kidney function, and mortality, but this
approach has not been tested in rigorous clinical trials.
Additional Readings
➢ Bart BA, Goldsmith SR, Lee KL, et al. Cardiorenal rescue
study in acute decompensated heart failure: rationale
and design of CARRESS-HF, for the Heart Failure
Clinical Research Network. J Card Fail. 2012;18(3):176182. +ESSENTIAL READING
➢ Costanzo MR, Negoianu D, Jaski BE, et al. Aquapheresis
versus intravenous diuretics and hospitalizations for
heart failure. JACC Heart Fail. 2016;4(2):95-105.
➢ Covic A, Copur S, Tapoi L, et al. Efficiency of
hypertonic saline in the management of decompensated heart failure: a systematic review and metaanalysis of clinical studies. Am J Cardiovasc Drugs.
2021;21(3):331-347.
➢ Damman K, Testani JM. The kidney in heart failure: an
update. Eur Heart J. 2015;36(23):1437-1444.
➢ Ellison DH. Clinical pharmacology in diuretic use. Clin J
Am Soc Nephrol. 2019;14(8):1248-1257. +ESSENTIAL READING
➢ Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in
patients with acute decompensated heart failure. N Engl J
Med. 2011;364(9):797-805. +ESSENTIAL READING
➢ Jentzer JC, DeWald TA, Hernandez AF. Combination of
loop diuretics with thiazide-type diuretics in heart
failure. J Am Coll Cardiol. 2010;56(19):1527-1534.
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➢ Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J
Med. 2003;348(14):1309-1321.
➢ Qavi AH, Kamal R, Schrier RW. Clinical use of diuretics
in heart failure, cirrhosis, and nephrotic syndrome. Int J
Nephrol. 2015;2015:975934.
➢ Tager T, Frohlich H, Grundtvig M, et al. Comparative
effectiveness of loop diuretics on mortality in the
treatment of patients with chronic heart failure - a
multicenter propensity score matched analysis. Int J
Cardiol. 2019;289:83-90.
➢ Cox ZL, Rao VS, Ivey-Miranda JB, et al. Compensatory
post-diuretic renal sodium reabsorption is not a
dominant mechanism of diuretic resistance in acute
heart failure. Eur Heart J. 2021;42(43):4468-4477.
End-Stage Liver Disease
Case 3: A 57-year-old man with ESLD is admitted to the
hospital with worsening ascites and dyspnea. He has a
history of hepatitis C, esophageal varices, and CKD G3bA1.
He is adherent to prescribed medications, including furosemide, spironolactone, and propranolol. BP is 102/58 mm Hg
and heart rate 90 beats per minute. Physical examination
reveals a tense, distended abdomen with dullness to percussion at both ﬂanks. His lungs are clear, and there is no
peripheral edema. Admission laboratory data include serum
sodium level of 130 mEq/L, serum urea nitrogen level of 41
mg/dL, Scr of 1.7 mg/dL (at baseline), and urine sodium
level <10 mEq/L.
Question 4: Which of the following is the next best
step in management?
a)
b)
c)
d)
e)

Albumin
Conivaptan
IV furosemide
Hydrochlorothiazide
Paracentesis

For the answer to the question, see the following text.

Guidelines recommend managing ascites in a stepwise
manner based on severity, starting with minimizing
ongoing liver damage and restricting sodium intake to <2
g/d. MRAs are considered among the most effective diuretics in ESLD, possibly because they (1) sidestep bile
acid– and free fatty acid–mediated inhibition of organic
anion (ie, sulfonamide) transport and (2) directly
antagonize increased RAS activity. Loop diuretics are
often coadministered with MRAs to increase efficacy.
Starting prescriptions of spironolactone 50-200 mg/d
and furosemide 40-160 mg/d, with titration every 3-4
days, is recommended to target net fluid loss of 1 L/d in
patients with edema or 0.5 L/d in those without edema.
A standard initial regimen is furosemide 40 mg and
spironolactone 100 mg, with progressive titration at the
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same ratio. Aggressive diuresis in patients without edema
risks intravascular volume depletion and AKI because
only 0.4 L/d ascites may be mobilized into the systemic
circulation. Patients with refractory ascites (<1.5 kg weight
loss per week while receiving dietary sodium <2 g/d and
maximally tolerated doses of diuretics) require largevolume paracentesis, transjugular intrahepatic portosystemic shunt creation, or liver transplant.
The patient in case 3 presents with severe (grade 3)
ascites while taking oral diuretics and should undergo
paracentesis. Albumin is infused during large-volume
paracentesis to maintain intravascular volume but, by
itself, would likely worsen volume overload. As
mentioned, attempting to increase diuresis by prescribing
IV furosemide or HCTZ would risk AKI in a patient
without peripheral edema. Conivaptan may improve
hyponatremia but would not increase natriuresis and
may be associated with adverse events such as
variceal bleeding in ESLD. The correct answer to question
4 is (e).
Additional Readings
➢ Gallo A, Dedionigi C, Civitelli C, Panzeri A, Corradi C,
Squizzato A. Optimal management of cirrhotic ascites: a
review for internal medicine physicians. J Transl Int Med.
2020;8(4):220-236.
➢ Runyon BA, Committee APG. Management of adult
patients with ascites due to cirrhosis: an update. Hepatology. 2009;49(6):2087-2107.
➢ Wong F. Management of ascites in cirrhosis. J Gastroenterol Hepatol. 2012;27(1):11-20.
CKD
Case 4: A 60-year-old woman with CKD G5A3 attributed
to type 2 diabetes began thrice-weekly hemodialysis 2
months earlier. Diabetes has been complicated by retinopathy, foot ulcers, peripheral vascular disease, and
autonomic neuropathy. The dialysis prescription includes a
blood ﬂow rate of 500 mL/min, dialysate ﬂow rate of 500
mL/min, time of 3.5 hours, and dry weight of 48 kg. Singlepool Kt/V averages 1.3, and 24-hour urine volume is
0.9 L. Although the patient has restricted salt and ﬂuid
intake, she has been unable to achieve her dry weight
because of intradialytic hypotension (IDH); systolic BP
usually decreases from 160 to 90 mm Hg during dialysis
and is accompanied by cramping and nausea when ultraﬁltration exceeds 1 L. Currently, predialysis BP is 158/92
mm Hg and heart rate 78 beats per minute. Physical examination reveals faint bilateral crackles, pitting edema
(2+), a stage 1 ﬁrst metatarsal ulcer, and a functioning
arteriovenous graft.
Question 5: Which of the following is the next best
step in management?
a) Increase dialysis time
b) Increase dry weight

c) Prescribe midodrine
d) Prescribe torsemide
e) Change to peritoneal dialysis
For the answer to the question, see the following text.

As CKD progresses, maintaining euvolemia requires
excreting the same sodium load with fewer nephrons. This
problem is exacerbated by systemic and intrarenal RAS
activation, which limits salt excretion. Volume overload in
CKD is generally treated by decreasing dietary sodium
intake and increasing urinary sodium excretion with loop
diuretic. Again, the diuretic response in CKD is blunted by
many of the problems listed in Box 1. The luminal concentration of loop diuretics in patients with stage 5 CKD is
only 10%-20% of that in individuals with normal kidney
function, so diuretic dose must be increased in advanced
CKD. Although thiazides were previously thought to be
ineffective at GFRs <30 mL/min/1.73 m2, recent evidence
suggests that chlorthalidone, specifically, may be an
effective antihypertensive and second-line diuretic in stage
4 CKD.
Diuretics may benefit patients receiving dialysis who
have residual kidney function. In patients undergoing
thrice-weekly hemodialysis, high interdialytic weight
gain necessitates a high ultrafiltration rate, which is
frequently complicated by IDH and predicts cardiovascular events and death. Conversely, loop diuretic use is
associated with decreased interdialytic weight gain and
less frequent IDH and hospitalization. Although peritoneal dialysis allows continuous ultrafiltration, volume
overload is common, and diuretics help minimize the use
of high-dextrose dialysates that may damage the peritoneal membrane.
Euvolemia cannot be achieved in the patient in case 4
because of IDH. Increasing dialysis time within reasonable constraints is unlikely to mitigate IDH. Increasing
dry weight would lessen IDH but worsen volume overload. Midodrine, an α1-adrenergic agonist, is frequently
used to manage IDH but may worsen clinical outcomes.
Changing from hemodialysis to peritoneal dialysis may
improve volume status, but modality choice involves
personal, logistical, and surgical considerations and
would not be the next best step in management. This
patient should initially take a loop diuretic to manage
hypervolemia and IDH, so the correct answer to question
5 is (d).
Additional Readings
➢ Brunelli SM, Cohen DE, Marlowe G, Van Wyck D. The
impact of midodrine on outcomes in patients with
intradialytic
hypotension.
Am
J
Nephrol.
2018;48(5):381-388.
➢ Sibbel S, Walker AG, Colson C, Tentori F, Brunelli SM,
Flythe J. Association of continuation of loop diuretics at
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hemodialysis initiation with clinical outcomes. Clin J Am
Soc Nephrol. 2019;14(1):95-102.
➢ Sinha AD, Agarwal R. Thiazide diuretics in chronic
kidney disease. Curr Hypertens Rep. 2015;17(3):13.
➢ Trinh E, Bargman JM. Are diuretics underutilized
in dialysis patients? Semin Dial. 2016;29(5):338341.
Nephrotic Syndrome
Case 5: A 24-year-old woman presents to the clinic for
ongoing management of nephrotic syndrome from minimal change disease. She initially presented 3 months
earlier with edema, proteinuria, and hypoalbuminemia and
was prescribed lisinopril and furosemide. Following
kidney biopsy 2 months earlier, prednisone, omeprazole,
and trimethoprim-sulfamethoxazole were added. During
the previous 3 months, urinary protein-creatinine ratio
has improved from 7.8 to 3.3 g/d and weight has decreased from 84 to 75 kg, but serum magnesium level
has remained low despite aggressive oral supplementation
with magnesium oxide. BP is 138/78 mm Hg and heart
rate 88 beats per minute. Physical examination is
signiﬁcant for pitting edema (1+). Laboratory data include
serum sodium level of 139 mEq/L, potassium level of
3.9 mEq/L, calcium level of 8.9 mg/dL, magnesium level of
1.2 mg/dL, serum urea nitrogen level of 23 mg/dL, and Scr
of 0.9 mg/dL (stable); urine sodium level is 82 mEq/L,
magnesium level is 29 mg/dL, and creatinine level is
121 mg/dL.
Question 6: Which of the following is the next best
step in managing hypomagnesemia?
a)
b)
c)
d)
e)

Prescribe IV magnesium chloride
Prescribe chlorthalidone
Prescribe amiloride
Discontinue furosemide
Discontinue omeprazole

For the answer to the question, see the following text.

Nephrotic syndrome is characterized by nephroticrange proteinuria (>3.5 g/d), hypoalbuminemia,
peripheral edema, and often hyperlipidemia and hypercoagulability. The genesis of edema has been
attributed to “underfill,” in which hypoalbuminemia
reduces the oncotic pressure gradient from serum to
interstitium, or “overfill,” in which the nephrotic
kidneys retain sodium and water. The underfill hypothesis has been criticized because the required
oncotic pressure gradient cannot be demonstrated
consistently; indeed, as serum albumin level decreases,
interstitial albumin level tends to decrease in parallel
because of dilution and lymphatic equilibration.
Conversely, the overfill hypothesis has become
increasingly attractive based on experimental and
clinical validation of the following sequence of events:
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heavy urinary filtration of plasminogen with urokinasemediated conversion to plasmin causes proteolytic
cleavage of the ENaC γ-subunit, constitutive ENaC
activation, and unregulated sodium reabsorption.
Increased sympathetic nervous system activity,
decreased response to atrial natriuretic peptide, and
abnormal expression of acid-sensing ion channel 2
may also contribute to sodium retention. However, the
observation that primary renal sodium retention causes
hypertension rather than edema as a result of pressure
natriuresis suggests that nephrotic edema may reflect a
mixture of underfill and overfill pathophysiology.
Some patients appear to exhibit decreased effective
arterial blood volume, especially children with minimal change disease.
As in most hypervolemic states, loop diuretics are
essential in managing nephrotic edema. Diuretic resistance may be attributable to decreased absorption from
GI tract edema, decreased delivery from hypoalbuminemia, and decreased secretion from intrarenal
edema (“nephrosarca”). Based on overfill pathophysiology, ENaC blockers may be useful adjuncts to loop
diuretics for volume management, even though clinical
evidence is scarce. Other diuretics, including thiazides
and CAIs, have also been effective in managing nephrotic
edema.
In case 5, proteinuria and edema are responding to
immunosuppression, RAS blockade, and diuresis, but
hypervolemia and hypomagnesemia remain. The fractional excretion of magnesium is 18%, indicating renal
magnesium wasting; thus, discontinuing omeprazole,
which would address GI magnesium wasting, would not
be useful. Similarly, changing from oral to IV magnesium
supplementation would not be expected to improve
hypomagnesemia while renal losses continue. Hypermagnesuria is almost certainly caused by furosemidemediated diuresis, but discontinuing this diuretic
could worsen volume overload while proteinuria
persists. Chlorthalidone and amiloride would both
augment diuresis, but only amiloride would increase
magnesium retention. The answer to question 6 is
therefore (c).
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